PB 90 of 2014
 
National Health Determination under paragraph 98C(1)(b) Amendment 2014
(No. 11)
_____________________________________________________________________
 
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.
 
Dated 25 November 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
 
 
1              Name of Instrument
(1)                This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 11).
(2)                This Instrument may also be cited as PB 90 of 2014.
2              Commencement                                                        
                This instrument commences on 1 December 2014.
3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)
                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).
Schedule 1            Amendments
 
[1]        Schedule 4, after entry for Escitalopram in the form Oral solution 10 mg
(as oxalate) per mL, 28 mL
insert in the column headed “Form (strength, type, size, etc.)”:
 
Oral solution 20 mg (as oxalate) per mL, 15 mL
[2]        Schedule 4, after entry for Fluticasone with Salmeterol in the form Powder for oral inhalation in breath actuated device containing fluticasone propionate
500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose,
60 doses
insert:

Fluticasone with vilanterol
Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

 
Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

[3]        Schedule 4, after entry for Trimethoprim with Sulfamethoxazole
insert:

Umeclidinium
Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses

Umeclidinium with vilanterol
Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses